Delcath Systems, Inc.
DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinicaā¦ read more
Healthcare
Medical Devices
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.06
Price+1.31%
$0.13
1Y
Price
Market Cap
$349.239m
Small
Price/Earnings 3y Avg5y Avg
335.3x
Premium
Premium
Financials Overview
Key metrics over the past few years+2.3%
EBITDA Margin+4.0%
Net Profit Margin+21.0%
Free Cash Flow MarginRevenue
$79.603m
+114.0%
1y CAGR+597.2%
3y CAGR+442.0%
5y CAGREarnings
$1.198m
+104.5%
1y CAGR+39.5%
3y CAGR+19.1%
5y CAGREPS
$0.01
+101.1%
1y CAGR+66.0%
3y CAGR+45.8%
5y CAGRBook Value
$114.847m
$124.295m
Assets$9.448m
Liabilities$965k
DebtDebt to Assets
0.8%
0.1x
Debt to EBITDAFree Cash Flow
$12.036m
+162.6%
1y CAGR+58.9%
3y CAGR+41.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company